vTv Therapeutics Inc.
Description
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.
About
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 10, 2025 | — | — | — | — |
| Aug 7, 2025 | — | — | — | — |
| May 7, 2025 | — | — | — | — |
| Mar 11, 2025 | — | — | — | — |
| Mar 13, 2024 | — | -1.67 | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 1 | — | 1 |
| Average estimate | — | -1.10 | — | -4.85 |
| Low estimate | — | -1.10 | — | -4.85 |
| High estimate | — | -1.10 | — | -4.85 |
| Last year EPS | — | — | — | -3.65 |
Growth estimates
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | — | 2.02M | 4.01M | 6.41M | 2.76M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 13.60M | 12.36M | 13.32M | 11.02M | 15.12M |
| Selling general and admin | 11.91M | 12.20M | 12.34M | 7.25M | 8.54M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -25.50M | -22.54M | -21.66M | -11.85M | -20.89M |
| Non operating interest income | |||||
| Income | 472,000 | 352,000 | 1,000 | 12,000 | 53,000 |
| Expense | 13,000 | 15,000 | 12,000 | 692,000 | 1.83M |
| Other income expense | -923,000 | -2.67M | 4.06M | -270,000 | 828,000 |
| Pretax income | -25.97M | -24.87M | -17.62M | -12.80M | -21.84M |
| Tax provision | — | 200,000 | 115,000 | — | 100,000 |
| Net income | -25.97M | -25.07M | -17.73M | -12.80M | -21.94M |
| Basic EPS | -9.71 | -10.40 | -8.40 | -7.20 | -23.60 |
| Diluted EPS | -9.71 | -10.40 | -8.40 | -7.20 | -23.60 |
| Basic average shares | 2.08M | 1.87M | 1.52M | 1.18M | 757,300 |
| Diluted average shares | 2.08M | 1.87M | 1.52M | 1.18M | 757,300 |
| EBITDA | -25.86M | -24.77M | -17.52M | -12.02M | -19.97M |
| Net income from continuing op. | -25.97M | -25.07M | -17.73M | -12.80M | -21.94M |
| Minority interests | 5.72M | 5.91M | 4.74M | 4.30M | 8.89M |
| Preferred stock dividends | — | — | — | — | 4.87M |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 11.02M | 33.24M | 25.47M | 14.79M | 9.27M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 9.45M | 12.13M | 13.42M | 5.75M | 1.78M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 102,000 | 173,000 | 57,000 | 158,000 | 5,000 |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | 1.11M | 2.55M | 2.01M | 1.31M | 1.06M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | — | — | — | — | 806,000 |
| Non current assets | |||||
| Properties | — | 349,000 | 402,000 | 482,000 | 543,000 |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 198,000 | 198,000 | 177,000 | 177,000 | 204,000 |
| Construction in progress | — | — | — | — | — |
| Leases | 406,000 | 406,000 | 406,000 | 406,000 | 405,000 |
| Accumulated depreciation | -487,000 | -397,000 | -305,000 | -216,000 | -148,000 |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | 5.59M | 9.17M | 6.73M | 2.48M |
| Other non current assets | — | — | — | — | 2.50M |
| Total liabilities | 29.57M | 27.40M | 10.25M | 11.00M | 18.11M |
| Current liabilities | |||||
| Accounts payable | 4.08M | 2.46M | 1.88M | 1.93M | 2.23M |
| Accrued expenses | 4.70M | 4.06M | 2.95M | 2.60M | 3.28M |
| Short term debt | 360,000 | 378,000 | 440,000 | 239,000 | 6.28M |
| Deferred revenue | 17,000 | 17,000 | 35,000 | 31,000 | 31,000 |
| Tax payable | — | — | — | — | — |
| Pensions | 1.47M | 788,000 | 3.20M | 1.59M | 1.56M |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 169,000 | 338,000 | 492,000 | 676,000 | 831,000 |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | 110,000 | 684,000 | 1.26M | 2.87M | 2.60M |
| Other non current liabilities | — | — | — | 50,000 | 260,000 |
| Shareholders equity | |||||
| Common stock | 27,000 | 27,000 | 901,000 | 773,000 | 641,000 |
| Retained earnings | -281.04M | -265.52M | -248.83M | -290.04M | -233.52M |
| Other shareholders equity | — | — | — | — | — |
| Total shareholders equity | -18.55M | 5.84M | 15.22M | 3.79M | -8.84M |
| Additional paid in capital | 256.34M | 254.76M | 238.19M | 209.16M | 183.86M |
| Treasury stock | — | — | — | — | — |
| Minority interest | 6.13M | 16.58M | 24.96M | 83.90M | 40.18M |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -25.97M | -25.07M | -17.73M | -12.80M | -21.94M | -23.85M | -54.65M | -55.35M | -41.11M | -36.10M | -48.20M |
| Depreciation | 90,000 | 92,000 | 89,000 | 94,000 | 39,000 | 218,000 | 197,000 | 265,000 | 501,000 | 864,000 | 1.09M |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 1.58M | 1.27M | 2.36M | 1.01M | 1.52M | 2.68M | 3.65M | 2.64M | 859,000 | — | 2.92M |
| Other Non-Cash Items | 213,000 | -337,000 | — | 380,000 | 532,000 | 1.01M | 1.03M | 154,000 | 722,000 | 4.92M | 10.47M |
| Accounts Receivable | 71,000 | -116,000 | 101,000 | -153,000 | -5,000 | 8.00M | -8.00M | 69,000 | -89,000 | -964,000 | -228,000 |
| Accounts Payable | — | -856,000 | 1.83M | -997,000 | -618,000 | -6.20M | — | — | — | — | — |
| Other Assets & Liabilities | -49,000 | 6.76M | -1.06M | 210,000 | -2.16M | -8.21M | 10.42M | -391,000 | -2.24M | -602,000 | -606,000 |
| Operating Cash Flow | -24.06M | -18.26M | -14.41M | -12.26M | -22.64M | -26.35M | -47.36M | -52.62M | -41.35M | -31.89M | -34.56M |
| Investing Activities | |||||||||||
| Capital Expenditures | — | -21,000 | — | — | -70,000 | -5,000 | -57,000 | -87,000 | -104,000 | -33,000 | -181,000 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | 4.40M | — | — | — | — | — | — | — | — | -140,000 | — |
| Purchase of Investments | — | — | — | — | — | — | — | — | — | — | — |
| Sale of Investments | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | 4.40M | -21,000 | — | — | 242,000 | 7,000 | -25,000 | -83,000 | -79,000 | 161,000 | -156,000 |
| Financing Activities | |||||||||||
| Long-Term Debt Issuance | 566,000 | 776,000 | 887,000 | 500,000 | 500,000 | 500,000 | 7.50M | 12.50M | 19.29M | 33.56M | 39.18M |
| Long-Term Debt Payments | -599,000 | -808,000 | -715,000 | -5.46M | -10.57M | -5.39M | — | -33,000 | -89,000 | -148,000 | -141,000 |
| Other Financing Charges | — | — | — | — | — | — | — | -673,000 | -1.42M | -148,000 | — |
| Financing Cash Flow | 11.40M | 13.95M | 26.21M | 14.01M | 12.30M | 11.22M | 7.50M | 11.76M | 123.56M | 30.77M | 40.81M |
| Other Cash Details | |||||||||||
| End Cash Position | 9.45M | 12.13M | 13.42M | 5.75M | 4.28M | 4.18M | 14.42M | 51.51M | 88.00M | 1.38M | 1.09M |
| Income Tax Paid | — | 200,000 | 115,000 | — | 100,000 | 1.00M | — | — | — | — | — |
| Interest Paid | 14,000 | 15,000 | 11,000 | 623,000 | 1.30M | 2.28M | 2.06M | 242,000 | 75,000 | 142,000 | 192,000 |
| Free Cash Flow | -19.08M | -16.04M | -19.31M | -18.00M | -23.09M | -26.86M | -44.62M | -48.30M | -37.05M | -30.81M | -41.87M |
Article
Article
Article
